

Evergreen builds strategic partnership with leading CDMO BOJIMED

June 5, 2023, BojiMed Pharmaceutical Technology (hereinafter referred to as "BOJIMED") and Evergreen Therapeutics (hereinafter referred to as "Evergreen") signed a strategic cooperation agreement. Adhering to the principle of "complementary advantages, mutual benefit and win-win", the two parties will use artificial intelligence (AI) to carry out strategic cooperation in the field of clinical trials, and jointly promote the efficient clinical development and commercialization of innovative drugs in multiple disease fields. By complementing each other's strengths and leveraging the advantages of their respective expert teams, they will use AI to solve bottleneck issues that affect drug research and development efficiency and costs in the clinical stage, thereby creating a new benchmark for innovative drug clinical research and development services.

Dr. Charles Lee, Chief Medical Officer of Evergreen, stated:

“I believe AI has the potential to revolutionize the way we conduct clinical trials, from identifying potential new drugs to monitoring patient progress. AI can be used to design more efficient and effective clinical trials. For example, it can help select the right patients for trials, determine the optimal dose and schedule of a drug, and predict which patients are most likely to benefit from treatment. AI can also be used to monitor patient progress during clinical trials and identify any potential side effects or safety issues that may arise, helping improve the safety and effectiveness of new drugs. In summary, artificial intelligence has the potential to make clinical trials more efficient, effective and safer. This could lead to faster development of new drugs at lower costs and better outcomes for patients.

“Evergreen has been focusing on building the clinical research and development advantages of its AI platform, which has been well verified in its self-developed pipeline. Two of its AI-designed pipelines have successfully entered Phase II clinical trials in the United States. We are very pleased to have reached a strategic cooperation with BOJIMED, which also focuses on the clinical field. By deeply integrating the unique clinical algorithm of our AI platform with BOJIMED’s powerful clinical trial service system and rich trial experience, we can help overcome technical difficulties in the clinical stage of drugs and improve the efficiency and success rate of clinical development for customers. We look forward to more Me-Only drugs being developed through such a powerful collaboration.”

Evergreen and BOJIMED have highly complementary industrial resources and technological synergy. The establishment of a strategic partnership with BOJIMED marks that Evergreen's AI R&D platform has been recognized by listed clinical CRO companies and has begun to be widely used in clinical settings.

About BOJIMED

Boji Pharmaceutical Technology (hereinafter referred to as "BOJIMED") is a company that provides "one-stop" outsourcing services (CRO+CDMO) for the entire R&D and production process of drugs and medical devices to pharmaceutical companies. The company has 120,000 square meters of modern office, experimental and production space, and currently has more than 1,300 employees. BOJIMED's services include new drug research and activity screening, pharmaceutical research (raw materials and preparations), drug evaluation (pharmacodynamics and toxicology), integrated services for small-molecule innovative drugs, clinical research, Sino-US dual registration services, CDMO production (MAH implementation), and technological achievement transformation, covering all stages of new drug research and development.